title: [Secondary amyloidosis in rheumatoid arthritis. A clinical study of 29 patients].
abstract: BACKGROUND
  To study the clinical features, outcome and response to therapy in 29 cases of rheumatoid arthritis (RA) with secondary amyloidosis (AA).
  
  
  METHODS
  Twenty-nine patients with RA and AA who were diagnosed during 11 years.
  
  
  RESULTS
  The mean age and the mean duration of RA were 63 +/- 12 years and 15 +/- 7 years respectively. The most common initial clinical feature was renal involvement (83%). Nineteen patients were treated with methotrexate. The mean survival time was 42 +/- 8 months. Eleven patients (38%) have deceased.
  
  
  CONCLUSIONS
  Our data confirms that AA in RA is a serious complication with a bleak prognosis. A normal renal function is a good prognosis indicator.
authors.affiliation: Servicio de Reumatología, Hospital Prínceps d'Espanya, Barcelona.
authors.forename: J
authors.initials: J
authors.lastname: Fiter Aresté
authors.forename: J M
authors.initials: JM
authors.lastname: Nolla Solé
authors.forename: C
authors.initials: C
authors.lastname: Gómez Vaquero
authors.forename: J
authors.initials: J
authors.lastname: Valverde García
authors.forename: D
authors.initials: D
authors.lastname: Roig Escofet
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate